Neuroscience Disease Areas

Our portfolio of unique capabilities and state-of-the-art instrumentation can support and advance your neuroscience research in various disease areas.

human nerve cell

At Charles River, we combine deep expertise and extensive capabilities to create innovative, flexible, and efficient solutions to advance neurological research and drug discovery. Our scientists continue to establish the most relevant in vitro and in vivo disease models to target acute and chronic neurological diseases. Our team is uniquely positioned to partner with clients, accelerating drug development from early discovery to the delivery of exciting new CNS therapies.

We offer disease specific models and assay systems to validate therapeutic modalities, including small molecules, biologics, and gene therapies for efficacy and safety. Our portfolio includes validated models with clinically relevant endpoints for established and emerging disease conditions.

Current therapies for Alzheimer’s disease (AD) primarily target tau and amyloid beta (Aβ) peptides and include inhibitors to reduce tau protein phosphorylation and BACE inhibitors to reduce Aβ levels. Aβ antibodies are also used to sequester free Aβ from plasma for clearance by the immune system. The development of effective AD therapies is very challenging and few compounds have shown significant benefits in clinical trials, primarily due to the lack of druggable targets and reliable biomarkers.

At Charles River, our scientists can guide you in the selection of the appropriate assay or disease model for every stage of the drug discovery process. Our extensive portfolio supports novel study designs and offers end-to-end validated in vitro services and in vivo models of pharmacology and toxicology. Our novel imaging modalities, behavioral tests and biomarker endpoint assays enable you to make effective decisions to help identify new therapies for Alzheimer’s disease.

Ask Us How We Can Support Your Program

We've included a list of our available capabilities and models below, and have answered some frequently asked questions about our Alzheimer’s disease models.

In Vitro Capabilities

In Vivo Models

Chronic and acute pain are high-interest areas for novel drug discovery. Analgesics that effectively block acute pain often do not work well for chronic pain management. Despite recent advances, many types of pain are still devoid of effective treatments. Preclinical in vivo and in vitro models are widely used to explore complex pain mechanisms as well as to screen novel therapies for pain.

At Charles River, we have developed validated models for in vitro and in vivo studies along with a comprehensive toolkit, including imaging, translational behavior and fine motor kinematics to accelerate novel therapies to treat acute and chronic pain. We offer comprehensive ion channel panels focused on pain as well as multiple in vivo readouts, including tactile and thermal hyperalgestia, cold allodynia, nocifensive behavior, fine motor kinematics, dynamic weight bearing and kinetic PET imaging.

Ask Us How We Can Support Your Program

We've included a list of our available capabilities and models below, and have answered some frequently asked questions about our pain models.

In Vitro Capabilities

In Vivo Models

We offer integrative neurological evaluations of objectively verifiable behavioral changes associated with movement disorders, such as:

  • Parkinson’s disease
  • Huntington’s disease
  • Dystonia, ataxias, and other paradoxical movement disorders